US Stock Movement: Agios plunges on October 30 as FDA postpones PDUFA and sickle cell disease news
Bitget异动解读2026/10/30 13:59Agios October 30 Major Drop Interpretation
Keywords: FDA postpones PDUFA, sickle cell disease
On October 30, 2026, Agios announced that the FDA has postponed the sNDA PDUFA target date for mitapivat in the treatment of sickle cell disease from November 1, 2026, to February 1, 2027. On October 9, 2026, the FDA requested additional information to assess whether REMS is required; the company responded on October 19, and the response was classified as a major amendment, extending the review period by three months.
(Disclaimer: This content is generated by AI technology by collecting and summarizing publicly available information, and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
S&P says Meta may reach the AA- downgrade threshold as early as 2027
S&P forecasts that Meta Platforms will fill its free cash flow gap with debt by 2028
The Dow Jones fell by 1.09%, the Nasdaq dropped 2.86%, and Intel plunged 28.58%.
Crypto prices
More
